CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

At the end of this year, we expect to begin reporting data from the REVEAL-1 open-label cohort of the REMAIN-1 study, which ...

We remain on track to report topline data from the study in December 2024,” said John Alam ... by a non-cash fair value adjustment to previously outstanding convertible notes, which converted into ...

We remain on track to report topline data from the study in December 2024," said John Alam ... by a non-cash fair value adjustment to previously outstanding convertible notes, which converted into ...

Increasingly sophisticated computer graphics and spatial 3D sound are combining to make the virtual world of games bigger, ...

A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialed by clinicians and ...

Generated $50.0 million in net revenue from sales of LUMRYZ™ ----2,300 patients on LUMRYZ as of September 30th, including 700 patients that ...

Her unique method blends physical movement with auditory processing, adding a social dimension to solo study time that helps ...

Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPARSubmitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ...

The study is entitled "A Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of Moderate to Severe Pain after ...

The growth of extended reality technology means new enhanced measures are needed to protect people's privacy, a new study ...